WO2003047558A3 - Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors - Google Patents

Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors Download PDF

Info

Publication number
WO2003047558A3
WO2003047558A3 PCT/IB2002/004805 IB0204805W WO03047558A3 WO 2003047558 A3 WO2003047558 A3 WO 2003047558A3 IB 0204805 W IB0204805 W IB 0204805W WO 03047558 A3 WO03047558 A3 WO 03047558A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxidase
amino acid
inhibitors
treatment
cns disorders
Prior art date
Application number
PCT/IB2002/004805
Other languages
French (fr)
Other versions
WO2003047558A2 (en
Inventor
Paul Moser
Original Assignee
Genset Sa
Paul Moser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, Paul Moser filed Critical Genset Sa
Priority to AU2002339696A priority Critical patent/AU2002339696A1/en
Publication of WO2003047558A2 publication Critical patent/WO2003047558A2/en
Publication of WO2003047558A3 publication Critical patent/WO2003047558A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to compounds that are inhibitors of D-amino acid oxidase, D-aspartate oxidase, or g34872; methods of treating CNS disorders including spinocerebellar ataxia, CAG repeat disorders, and other ataxic disorders using the compounds; and pharmaceutically acceptable compositions that contain the inhibitors are disclosed.
PCT/IB2002/004805 2001-12-03 2002-10-29 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors WO2003047558A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002339696A AU2002339696A1 (en) 2001-12-03 2002-10-29 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33658301P 2001-12-03 2001-12-03
US60/336,583 2001-12-03

Publications (2)

Publication Number Publication Date
WO2003047558A2 WO2003047558A2 (en) 2003-06-12
WO2003047558A3 true WO2003047558A3 (en) 2004-03-25

Family

ID=23316743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004805 WO2003047558A2 (en) 2001-12-03 2002-10-29 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors

Country Status (2)

Country Link
AU (1) AU2002339696A1 (en)
WO (1) WO2003047558A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9485988B2 (en) 2008-06-26 2016-11-08 Suncor Energy Inc. Turfgrass fungicide formulation with pigment

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529486A1 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof
CA2472806A1 (en) 2004-05-18 2005-11-18 Petro-Canada Compositions and methods for treating turf insect pests and diseases such as fungal infestations
US20060111442A1 (en) * 2004-11-20 2006-05-25 Mr. Stanley Antosh Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD.
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
US9357768B2 (en) 2006-10-05 2016-06-07 Suncor Energy Inc. Herbicidal composition with increased herbicidal efficacy
FR2929115B1 (en) * 2008-03-31 2010-06-04 Exsymol Sa COSMETIC USE OF CONJUGATED COMPOUNDS OF INDOLIC AUXINS.
CA3037010A1 (en) 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
EP2613635B1 (en) 2010-09-09 2016-04-06 Suncor Energy Inc. Synergistic paraffinic oil and boscalid fungicides
JO3115B1 (en) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
US9889222B2 (en) 2011-11-09 2018-02-13 Kimberly-Clark Worldwide, Inc. Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness
US8791045B2 (en) 2011-11-09 2014-07-29 Kimberly-Clark Worldwide, Inc. Non-tacky wetness indicator composition for application on a polymeric substrate
AU2012337781B2 (en) 2011-11-15 2017-07-06 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
BR112017025499A2 (en) * 2015-05-28 2018-08-07 Baylor College Medicine Benefits Of N-Acetyl Cysteine And Glycine Supplementation To Improve Glutathione Levels
CA2938096C (en) 2016-08-04 2019-02-26 Suncor Energy Inc. Stabilized emulsions
CN108420810A (en) * 2018-02-11 2018-08-21 华南农业大学 Phenylpyruvic acid is preparing the application in alleviating or improving the product of anxiety and Depressive behavior
RU2751003C1 (en) * 2020-07-29 2021-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) Use of sulfonates for inhibiting human lactate dehydrogenase a
CN115745848A (en) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 Processing and synthesizing process of aminoguanidine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950406A2 (en) * 1998-01-26 1999-10-20 Niigata University Remedy for CAG repeat expansion diseases
WO1999065516A1 (en) * 1998-06-17 1999-12-23 Yeda Research And Development Co. Ltd. Methods and compositions for treating diseases mediated by transglutaminase activity
WO2000011952A1 (en) * 1998-08-31 2000-03-09 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2002066672A2 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950406A2 (en) * 1998-01-26 1999-10-20 Niigata University Remedy for CAG repeat expansion diseases
WO1999065516A1 (en) * 1998-06-17 1999-12-23 Yeda Research And Development Co. Ltd. Methods and compositions for treating diseases mediated by transglutaminase activity
WO2000011952A1 (en) * 1998-08-31 2000-03-09 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2002066672A2 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEERS M H ET AL.: "The Merck Manual, 17th ed.", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002246495 *
GISPERT S ET AL: "Localization of the candidate gene D-amino acid oxidase outside the refined I-cM region of spinocerebellar ataxia 2.", AMERICAN JOURNAL OF HUMAN GENETICS. UNITED STATES OCT 1995, vol. 57, no. 4, October 1995 (1995-10-01), pages 972 - 975, XP009013160, ISSN: 0002-9297 *
LARSON JEFFREY L ET AL: "The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats.", PHARMACOLOGY & TOXICOLOGY, vol. 78, no. 1, 1996, pages 44 - 49, XP009013100, ISSN: 0901-9928 *
PHANJOO A L ET AL: "Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people", ACTA PSYCHIATRICA SCANDINAVICA 1991 DENMARK, vol. 83, no. 6, 1991, pages 476 - 479, XP009013266, ISSN: 0001-690X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9485988B2 (en) 2008-06-26 2016-11-08 Suncor Energy Inc. Turfgrass fungicide formulation with pigment

Also Published As

Publication number Publication date
AU2002339696A8 (en) 2003-06-17
WO2003047558A2 (en) 2003-06-12
AU2002339696A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003047558A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2002041889A3 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
WO2002046129A3 (en) Inhibitors of histone deacetylase
WO2002066672A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
AU2001233081A1 (en) Composition for treatment of stress
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
MXPA04004939A (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them.
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2002007669A3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
WO2004032908A3 (en) Method of inhibiting angiogenesis
AU2002367023A1 (en) Compositions and methods for treating heart failure
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2002365057A1 (en) Compositions and methods for treating heart failure
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP